Placenta Previa Clinical Trial
Official title:
Intramuscular 17-Alpha-Hydroxyprogesterone Caproate for Prevention of Emergent Cesarean Delivery in Symptomatic Pregnant Women With Placenta Previa: A Randomized Controlled Study
Purpose to evaluate the effects of intramuscular 17-Alpha-Hydroxyprogesterone Caproate (17-OHPC) for prevention of Emergent Cesarean Delivery in symptomatic Pregnant Women with Placenta Previa
Most authors report an increased risk of bleeding with advancing gestation among women with
placenta previa.
The American College of Obstetricians and Gynecologists (ACOG) and the Society for
Maternal-Fetal Medicine (SMFM) both recommend the use of 17-OHPC to prevent recurrent
spontaneous preterm birth.
Preterm deliveries account for 75% of perinatal mortality and surviving preterm infants are
at risk for neurological, respiratory, and gastrointestinal complications. So, it is
therefore very important to try to prolong the pregnancy without increasing the risk of
emergent delivery in cases with placenta previa. The authors hypothesized that a
pharmacological strategy like 17-alpha-Hydroxyprogesterone caproate may improve pregnancy
outcomes and may also allow obstetricians to tailor their approach to save delayed scheduled
cesarean section women with a placenta previa.
The aim of this study to evaluate the role of17-alpha-Hydroxyprogesterone caproate in the
prevention of preterm cesarean delivery (CD) in cases with symptomatic placenta previa with
avoids of an emergent CD which affects the maternal outcome and prevents prematurity which
affects the prenatal outcome.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04518163 -
Bakri Balloon Plus Tranexamic Acid During Cesarean Delivery for Placenta Previa
|
N/A | |
| Recruiting |
NCT04518150 -
Combined Bilateral Uterine Artery Ligation and Bakri Balloon During Cesarean Section
|
N/A | |
| Recruiting |
NCT03638024 -
Cell-free Fetal DNA Concentration in Cases of Abnormal Placental Invasion .
|
||
| Terminated |
NCT01996345 -
Vaginal Pessary Versus Expectant Management for Placenta Previa
|
N/A | |
| Recruiting |
NCT04609527 -
Management of Placenta Accreta Spectrum
|
Phase 2/Phase 3 | |
| Completed |
NCT03431116 -
Low Implanted Second Trimester Placenta and Placenta Previa
|
N/A | |
| Completed |
NCT03321435 -
The Placenta Previa and Fetal Weight
|
N/A | |
| Enrolling by invitation |
NCT05529381 -
Anxiety and Depressive Symptoms in Placenta Previa / Accreta
|
||
| Completed |
NCT04264234 -
Management Of Placenta Previa Cases And Determination Of Hospitalization Criteria
|
N/A | |
| Completed |
NCT05340205 -
Blood Loss During Cesarean Delivery in Placenta Previa Patients
|
Phase 4 | |
| Completed |
NCT03570723 -
Glove-loaded Foley's Catheter Tamponade for Cesarean Section for Placenta Previa
|
N/A | |
| Completed |
NCT05283122 -
Mostafa Maged Technique to Control and Prevent the Post-Partum Bleeding From the Lower Uterine Segment in Placenta Previa Cases
|
N/A | |
| Withdrawn |
NCT01442207 -
Cerclage for Prevention on Preterm Birth in Women With Placenta Previa
|
Phase 3 | |
| Not yet recruiting |
NCT03451136 -
Cervical Length in Cases of Placenta Previa
|
N/A | |
| Completed |
NCT02966197 -
Efficacy of Prophylactic Internal Iliac Artery Balloon Catheterization in the Management of Placenta Previa and Accreta
|
N/A | |
| Recruiting |
NCT02590484 -
The Cervix as a Natural Tamponade in Postpartum Hemorrhage Caused by Placenta Previa and Placenta Previa Accreta
|
N/A | |
| Recruiting |
NCT05802251 -
Sonographic Parameters and Risk of Antepartum Hemorrhage in Asymptomatic Women With Placenta Previa: A Cohort Study
|
||
| Completed |
NCT03542552 -
Nifedipine Versus Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa
|
Phase 3 | |
| Recruiting |
NCT03124472 -
Effect of Uterine Artery Ligation Prior to Uterine Incision in Women With Placenta Previa
|
N/A | |
| Recruiting |
NCT03633175 -
Progesterone in Patients With Placenta Previa
|
Phase 2 |